Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT Combined With QL1706 Plus Bevacizumab as First-line Treatment for Advanced HCC
NCT07847671Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Oct 2026
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Fecal Microbiota Transplantation Capsule, iparomlimab, tuvonralimab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Objective Response Rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
Fecal Microbiota Transplantation Capsuleiparomlimabtuvonralimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07847671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07847671.